Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|April 15, 2022
The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sampleEva Wibbeler, Miriam Nickel, Christoph Schwering, et al.
Frontiers in Human Neuroscience|December 28, 2020
Long Term Follow-Up on Pediatric Cases With Congenital Myasthenic Syndromes-A Retrospective Single Centre Cohort StudyAdela Della Marina, Eva Wibbeler, Angela Abicht, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|December 22, 2019
Cardiac pathology in neuronal ceroid lipofuscinoses (NCL): More than a mere co-morbidityKatja Rietdorf, Emily E Coode, Angela Schulz, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|June 2, 2022
Visual perception and macular integrity in non-classical CLN2 diseaseYevgeniya Atiskova, Jan Wildner, Eva Wibbeler, et al.
Eye and Brain|November 19, 2024
Peripapillary Retinal Nerve Fiber Layer (pRNFL) Thickness - A Novel Biomarker of Neurodegeneration in Late-Infantile CLN2 DiseaseNikolaos Gkalapis, Simon Dulz, Carsten Grohmann, et al.
Journal of Child Neurology|February 5, 2021
Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 PatientsChristoph Schwering, Gertrud Kammler, Eva Wibbeler, et al.
American Journal of Ophthalmology|July 25, 2020
An Ophthalmic Rating Scale to Assess Ocular Involvement in Juvenile CLN3 DiseaseSimon Dulz, Yevgeniya Atiskova, Eva Wibbeler, et al.
The British Journal of Ophthalmology|June 30, 2022
Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)Simon Dulz, C Schwering, Jan Wildner, et al.
Frontiers in Neurology|March 31, 2025
Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfaAngela Schulz, Christoph Schwering, Eva Wibbeler, et al.
Journal of Inherited Metabolic Disease|May 23, 2026
Mapping Clinical Progression to Brain Atrophy in CLN2 Patients Under Cerliponase Alfa Treatment: A Prospective Neuroimaging StudyMarvin Petersen, Lena Marie Westermann, Luca Hagenah, et al.
Pageof 2